InflaRx (IFRX) News Today $2.50 +0.03 (+1.21%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Short Interest in InflaRx (NASDAQ:IFRX) Expands By 15.0%InflaRx (NASDAQ:IFRX - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 248,900 shares, an increase of 15.0% from the December 15th total of 216,500 shares. Based on an average daily trading volume, of 264,900 shares, the days-to-cover ratio is currently 0.9 days.January 19 at 2:28 PM | marketbeat.comInflaRx's (IFRX) Buy Rating Reiterated at HC WainwrightJanuary 19 at 2:46 AM | americanbankingnews.comInflaRx: Strategic Buy Rating Amidst Regulatory Milestones and Promising PipelineJanuary 18, 2025 | markets.businessinsider.comInflaRx’s Market Potential Bolstered by EU Approval of GohibicJanuary 16, 2025 | markets.businessinsider.comInflaRx stock reiterated at Buy at H.C. Wainwright after EU drug approvalJanuary 16, 2025 | msn.comInflaRx (NASDAQ:IFRX) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $8.00 price target on shares of InflaRx in a report on Thursday.January 16, 2025 | marketbeat.comInflaRx announces EC grants marketing authorization to Gohibic for ARDSJanuary 15, 2025 | markets.businessinsider.comInflaRx Secures EU Approval for GOHIBIC in Treating COVID-19-Induced ARDSJanuary 15, 2025 | tipranks.comInflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)January 15, 2025 | globenewswire.comInflaRx Announces Participation in January Events in San FranciscoJanuary 7, 2025 | markets.businessinsider.comShort Interest in InflaRx (NASDAQ:IFRX) Increases By 37.9%InflaRx (NASDAQ:IFRX - Get Free Report) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 216,500 shares, an increase of 37.9% from the November 30th total of 157,000 shares. Based on an average daily volume of 243,600 shares, the short-interest ratio is presently 0.9 days.December 30, 2024 | marketbeat.comInflaRx announces first patient dosed in 2a study of CSU, HSDecember 20, 2024 | markets.businessinsider.comInflaRx Begins Phase 2a Trial for Innovative Anti-Inflammatory DrugDecember 20, 2024 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for InflaRx (NASDAQ:IFRX)HC Wainwright reissued a "buy" rating and set a $8.00 target price on shares of InflaRx in a report on Friday.December 20, 2024 | marketbeat.comInflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904December 20, 2024 | globenewswire.comInflaRx (NASDAQ:IFRX) Shares Up 3.8% - Still a Buy?InflaRx (NASDAQ:IFRX) Trading Up 3.8% - Time to Buy?December 6, 2024 | marketbeat.comInflaRx initiated with a Buy at Lucid CapitalNovember 20, 2024 | markets.businessinsider.comIs InflaRx N.V. (IFRX) the Best German Stock to Buy Now?November 20, 2024 | msn.comInflaRx Shares Rise 12% After Regulators Favor Authorization of GohibicNovember 16, 2024 | marketwatch.comInflaRx receives positive CHMP opinion for SARS-CoV-2-induced acute respiratory distress treatmentNovember 16, 2024 | msn.comInflaRx receives positive CHMP opinion for GOHIBIC for SARS-CoV-2-induced ARDSNovember 16, 2024 | markets.businessinsider.comLifeSci Capital Reaffirms Their Hold Rating on InflaRx (IFRX)November 16, 2024 | markets.businessinsider.comInflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress SyndromeNovember 15, 2024 | globenewswire.comFY2024 EPS Estimates for InflaRx Decreased by HC WainwrightInflaRx (NASDAQ:IFRX - Free Report) - Research analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for shares of InflaRx in a report issued on Monday, November 11th. HC Wainwright analyst E. White now expects that the company will post earnings of ($1.05) per shareNovember 14, 2024 | marketbeat.comFY2024 EPS Estimates for InflaRx Cut by Leerink PartnrsInflaRx (NASDAQ:IFRX - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2024 earnings per share estimates for InflaRx in a research note issued to investors on Monday, November 11th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($1.02) pNovember 14, 2024 | marketbeat.comInflaRx’s Strategic Advancements and Robust Financial Health Support Buy RatingNovember 13, 2024 | markets.businessinsider.comLifeSci Capital Keeps Their Hold Rating on InflaRx (IFRX)November 13, 2024 | markets.businessinsider.comInflaRx’s Promising Market Potential and Financial Stability Justify Buy RatingNovember 12, 2024 | markets.businessinsider.comInflaRx Reports Q3 2024 Financial Results and ProgressNovember 11, 2024 | tipranks.comInflaRx (NASDAQ:IFRX) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $8.00 price objective on shares of InflaRx in a report on Monday.November 11, 2024 | marketbeat.comInflaRx Reports Rising Revenue Amidst Significant LossesNovember 9, 2024 | markets.businessinsider.comInflaRx expects cash to fund operations into 2026November 9, 2024 | finance.yahoo.comInflaRx Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 8, 2024 | globenewswire.comEarnings Preview: InflaRxNovember 7, 2024 | benzinga.comInflaRx (IFRX) Set to Announce Earnings on FridayInflaRx (NASDAQ:IFRX) will be releasing earnings before the market opens on Friday, November 8, Zacks reports.November 1, 2024 | marketbeat.comInflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation ConferenceOctober 31, 2024 | finance.yahoo.comInflaRx (NASDAQ:IFRX) Sees Significant Growth in Short InterestInflaRx (NASDAQ:IFRX - Get Free Report) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 262,900 shares, an increase of 63.2% from the September 15th total of 161,100 shares. Based on an average daily volume of 59,400 shares, the short-interest ratio is presently 4.4 days.October 14, 2024 | marketbeat.comInflaRx (NASDAQ:IFRX) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comBuy Rating on InflaRx as Gohibic Shows Promise and Financials StrengthenSeptember 26, 2024 | markets.businessinsider.comInflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology CongressSeptember 25, 2024 | globenewswire.com3 Penny Stocks To Buy With Just $750September 24, 2024 | 247wallst.comInflaRx (NASDAQ:IFRX) Shares Up 1.3%InflaRx (NASDAQ:IFRX) Trading 1.3% HigherSeptember 4, 2024 | marketbeat.comInflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human DiseasesSeptember 3, 2024 | globenewswire.comInflaRx (NASDAQ:IFRX) Short Interest Down 9.2% in AugustInflaRx (NASDAQ:IFRX - Get Free Report) was the target of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling 227,600 shares, a decrease of 9.2% from the July 31st total of 250,600 shares. Based on an average trading volume of 99,000 shares, the days-to-cover ratio is presently 2.3 days.September 1, 2024 | marketbeat.comInflaRx Announces Participation in September Investor EventsAugust 27, 2024 | globenewswire.comIFRX Sep 2024 2.500 call (IFRX240920C00002500)August 18, 2024 | finance.yahoo.comInflaRx Buy Rating Backed by Promising Drug Prospects and Financial StabilityAugust 13, 2024 | markets.businessinsider.comShort Interest in InflaRx (NASDAQ:IFRX) Rises By 281.4%InflaRx (NASDAQ:IFRX - Get Free Report) was the target of a significant growth in short interest in July. As of July 31st, there was short interest totalling 250,600 shares, a growth of 281.4% from the July 15th total of 65,700 shares. Based on an average daily volume of 128,800 shares, the short-interest ratio is currently 1.9 days.August 13, 2024 | marketbeat.comInflaRx N.V.: InflaRx Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 8, 2024 | finanznachrichten.deInflaRx Buy Rating Affirmed: Financial Stability and Gohibic’s Market PotentialAugust 8, 2024 | markets.businessinsider.com Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address IFRX Media Mentions By Week IFRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IFRX News Sentiment▼0.760.64▲Average Medical News Sentiment IFRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IFRX Articles This Week▼71▲IFRX Articles Average Week Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cullinan Therapeutics News Today Dianthus Therapeutics News Today Autolus Therapeutics News Today CARGO Therapeutics News Today Kura Oncology News Today Humacyte News Today Opthea News Today Mind Medicine (MindMed) News Today Erasca News Today Verve Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IFRX) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTexas embraces new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredThe Stock I’m Calling My #1 of the DecadeThe stock I reveal right here is my #1 stock of the decade. In fact, it might be my favorite stock ever. ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IFRX Stock Alerts